Posts Tagged ‘hypertensive’

Women With High Blood Pressure During Pregnancy Face Future Of Complications

Posted by poster on January 31st, 2009 under Uncategorized Tags: , , ,  •  Comments Off

Chronic hypertension, diabetes and blood clots are more likely in otherwise healthy women who experienced complications due to hypertension such as preeclampsia in their first pregnancies, according to Yale School of Medicine researchers working in collaboration with the University of Copenhagen, Denmark.
The findings are presented in an abstract at the Society for Maternal Fetal Medicine […]

Protease Inhibitor That May Aid In Diabetic Retinopathy Treatment Described By Researchers

Posted by poster on January 23rd, 2009 under Uncategorized Tags: , , ,  •  Comments Off

Researchers from Joslin Diabetes Center, Boston, and ActiveSite Pharmaceuticals, Inc., San Francisco, have announced that they have demonstrated that a specific inhibitor of the protease plasma kallikrein, ASP-440, developed by ActiveSite Pharmaceuticals, may provide a new therapeutic approach for treatment of diabetic retinopathy, the most common eye-related complication of diabetes. The study, which

Drug Designed To Lower Uric Acid Levels May Be Useful For Hypertension

Posted by poster on December 30th, 2008 under Uncategorized Tags: , , , ,  •  Comments Off

According to a report published in the August 27 issue of JAMA,
a drug that lowers uric acid levels, allopurinol, also seems to lower
blood pressure in adolescents with newly diagnosed hypertension (high
blood pressure).
Hyperuricemia - a condition characterized by higher than normal blood
levels of uric acid

New Antihypertensive PritorPlus® 80/25 And Kinzalkomb® 80/25 Approved By EU Commission

Posted by poster on December 29th, 2008 under Uncategorized Tags: , , , , ,  •  Comments Off

Bayer Schering Pharma was granted European marketing authorization for its new antihypertensive fixed dose combination drug PritorPlus® 80/25 and Kinzalkomb® 80/25 (80 mg telmisartan/25 mg hydrochlorothiazide) by the European Commission. The new formulation will be launched in Germany later this month, to be followed soon by selected

Allopurinol May Lower Blood Pressure In Teens With Hypertension

Posted by poster on December 8th, 2008 under Uncategorized Tags: , , , ,  •  Comments Off

The drug allopurinol, which lowers uric acid levels, appears to reduce blood pressure in adolescents with newly diagnosed hypertension, according to a preliminary report in the August 27 issue of JAMA.
Hypertension is commonly associated with hyperuricemia (elevated blood level of uric acid, a by-product of normal chemical

Single Pill Combinations Diovan HCT® And Exforge® Approved In US As First-line Treatments For High Blood Pressure

Posted by poster on December 8th, 2008 under Uncategorized Tags: , , , , , , ,  •  Comments Off

The US Food and Drug Administration (FDA) has approved two single-pill combination medications, Diovan HCT® (valsartan and hydrochlorothiazide) and Exforge® (amlodipine and valsartan), as initial or ‘first-line’ therapies in patients likely to need multiple drugs to achieve their blood pressure goals.
The FDA approval of

Rasilez®, First-in-class Direct Renin Inhibitor, Provides Greater Reduction In High Blood Pressure Than ACE Inhibitor Ramipril

Posted by poster on December 7th, 2008 under Uncategorized Tags: , , , , , , ,  •  Comments Off

New clinical data presented show first-in-class direct renin inhibitor Rasilez® (aliskiren), known as Tekturna® in the US, provides significantly greater blood pressure reductions in patients with high blood pressure aged 65 and over, compared to the angiotensin-converting enzyme (ACE) inhibitor ramipril[1].
Results from the

Blood Pressure Variability And Classification Of Prehypertension And Hypertension In Adolescence

Posted by poster on December 5th, 2008 under Uncategorized Tags: , , ,  •  Comments Off

UroToday.com - A study by Dr. Bonita Falkner, et al., examined the presence and persistence of the prehypertension and hypertension classifications as well as the progression of prehypertension to hypertension in pediatrics. They analyzed the data from the National Childhood Blood Pressure database to

NicOx’ Naproxcinod Shows Highly Significant Reduction In Daytime Blood Pressure Versus Naproxen

Posted by poster on December 2nd, 2008 under Uncategorized Tags: , , , ,  •  Comments Off

NicOx
Generic ultram pills no prescription S.A. (Euronext Paris: COX) announced that a new analysis of the data
from the 104 Ambulatory Blood Pressure Monitoring (ABPM) study for
naproxcinod was presented yesterday at the American Heart Association
Scientific Sessions

NicOx Announces Favorable Blood Pressure Data For Naproxcinod In A Large ABPM Study

Posted by poster on December 2nd, 2008 under Uncategorized Tags: , , , , ,  •  Comments Off

NicOx
S.A. (Euronext Paris: COX) announced positive top-line results from a
118 patient Ambulatory Blood Pressure Monitoring (ABPM) trial (the 111
study), which compared the 24-hour blood pressure profile of escalating
doses of naproxcinod and naproxen in osteoarthritis (OA) patients with
controlled hypertension.

Hypertension Disparity Linked To Environment

Posted by poster on December 1st, 2008 under Uncategorized Tags: , ,  •  Comments Off

Social environment may play a greater role in the disparity between the numbers of African Americans living with hypertension compared to non-Hispanic whites with the disease. A study by researchers at the Johns Hopkins Bloomberg School of Public Health found that the disparity was substantially reduced when comparing groups of African Americans and non-Hispanic whites […]

Olive Leaf Extract Can Help Tackle High Blood Pressure And Cholesterol

Posted by poster on November 23rd, 2008 under Uncategorized Tags: , , ,  •  Comments Off

Taking 1000mg of a specific olive leaf extract (EFLA®943) can lower cholesterol and lower blood pressure in patients with mild hypertension (high blood pressure). These findings came from a ‘Twins’ trial, in which different treatments were given to identical twins. By doing this, researchers could increase the power of their data by eliminating some of […]

Guideline On Diagnosis And Treatment Of Primary Aldosteronism Released By Endocrine Society

Posted by poster on November 22nd, 2008 under Uncategorized Tags: , , ,  •  Comments Off

The Endocrine Society has released a new clinical practice guideline for the detection, diagnosis, and treatment of patients with primary aldosteronism. The guidelines appear in the September issue of the Journal of Clinical Endocrinology & Metabolism (JCEM), a publication of The Endocrine Society.
Primary aldosteronism (PA) refers to conditions in which production of aldosterone, a steroid […]

Blood Pressure Measured In Doctor’s Office May Not Adequately Predict Heart Risks

Posted by poster on August 3rd, 2008 under Uncategorized Tags: , , ,  •  Comments Off

Blood pressure, as measured in a medical office, does not seem to predict future heart risks, in comparison with continuous blood pressure monitoring in individuals with treatment-resistant hypertension, according to an article released on November 24, 2008 in Archives of Internal Medicine, on of the JAMA/Archives journals.
Between 10 and 30% of patients with high blood […]

American Society Of Hypertension Updates Guidelines To Address 7-Fold Mortality Increase In Hypertensive Patients With Diabetes

Posted by poster on March 26th, 2008 under Uncategorized Tags: , , ,  •  Comments Off

Buy fosamax without prescription Updated guidance published in the current issue of the American Society of Hypertension’s (ASH) Journal of Clinical Hypertension addresses the urgent need for

NicOx Completes Enrollment Of Two Ambulatory Blood Pressure Measurement (ABPM) Studies For Naproxcinod In Hypertensive OA Patients

Posted by poster on March 1st, 2008 under Uncategorized Tags: , , , , ,  •  Comments Off

NicOx S.A.
(Euronext Paris: COX) announced it has successfully completed the
enrollment of 417 osteoarthritis (OA) patients with controlled hypertension
in two clinical pharmacology studies in the United States, in line with
previously announced timelines. These trials are designed to assess the
blood